Table 2

Pharmacokinetic parameters of [³H]DGX after i.v. administration to rats

	Dose of PSC 833
	Control	0.1 mg/kg	0.3 mg/kg	3 mg/kg
AUC_{0–360 min} (Fd × min/ml)	0.415 ± 0.022	0.812 ± 0.031^2-160	0.737 ± 0.047^2-160	0.868 ± 0.029^2-160
X_{liver,360 min} (Fd/g liver)	0.00563 ± 0.00115	0.00918 ± 0.00099	0.011 ± 0.003^2-150	0.013 ± 0.002^2-160
X_{bile,0–360 min} (Fd)	0.309 ± 0.024	0.0986 ± 0.0085^2-160	0.109 ± 0.017^2-160	0.108 ± 0.013^2-160
X_{urine,0–360 min} (Fd)	0.112 ± 0.020	0.104 ± 0.037	0.184 ± 0.058	0.168 ± 0.043
CL_bile (ml/min/kg)	3.03 ± 0.35	0.486 ± 0.038^2-160	0.595 ± 0.085^2-160	0.506 ± 0.081^2-160
CL_R (ml/min/kg)	1.12 ± 0.24	0.516 ± 0.184	0.961 ± 0.286	0.768 ± 0.188

[³H]DGX was administered i.v. to rats that had received an i.v. injection of PSC 833 (0, 0.1, 0.3, and 3 mg/kg) 30 min before the experiments. Amount of [³H]DGX in the plasma, bile, and urine specimens was determined with HPLC. The plasma concentration-time profiles of [³H]DGX are shown in Fig. 2. Kinetic parameters were calculated as described in the text. X_liver represents the fraction of administered dose (Fd) associated with 1 g liver at 6 h after administration. Results are given as the mean ± S.E. of four independent experiments.

↵2-150 P < .05, significantly different from control, using Fisher’s t test.
↵2-160 P < .01, significantly different from control, using Fisher’s t test.